Synlogic, Inc. (SYBX)
| Market Cap | 173.16M |
| Revenue (ttm) | 545,000 |
| Net Income (ttm) | -59.17M |
| Shares Out | 35.84M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $3.09 |
| Previous Close | $3.42 |
| Change ($) | -0.33 |
| Change (%) | -9.65% |
| Day's Open | 3.40 |
| Day's Range | 3.08 - 3.40 |
| Day's Volume | 277,515 |
| 52-Week Range | 1.78 - 5.11 |
Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...
CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of i...
CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has com...
CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 stu...
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on S...
CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...
CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial ...
CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB...
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Compa...
CAMBRIDGE, Mass., Feb. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...
CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biolog...
Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant...
Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...
CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 h...
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appoint...
CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it wil...
Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript
Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36), which b...
CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial re...
CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Compan...
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it wi...
CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.
With a low capital cost and solid growth potential, many investors prefer to invest in penny stocks. Here are the top stocks to buy this year.
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announc...
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020. The event will provide ...
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announc...
Synlogic: A Clinical-Stage Biopharma With A Good Risk/Reward Ratio
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2020 Results - Earnings Call Transcript
Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2019 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Synlogic.
With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2...
As of late, it has definitely been a great time to be an investor Synlogic
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Shares of Synlogic Inc. SYBX, +4.77% sank 9.3% toward a record low in premarket trading Tuesday, after the biotechnology company said it has discontinued the development of SYNB1020 for the treatment of...
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2019 Results - Earnings Call Transcript
Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Synlogic (NASDAQ: SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.
Ginkgo Bioworks and Synlogic to collaborate on 'living medicine'
Bioengineers are reprogramming bacteria in our bodies to create living medicine.
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumo... [Read more...]
| Industry Biotechnology | |
| CEO Aoife Brennan | Employees 72 |
| Stock Exchange NASDAQ | Ticker Symbol SYBX |
Financial Performance
In 2020, Synlogic's revenue was $545,000, a decrease of -75.49% compared to the previous year's $2.22 million. Losses were -$59.17 million, 15.2% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 10.71, which is an increase of 246.60% from the latest price.